Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Cyclophosphamide (Primary) ; Interleukin-2 (Primary) ; Ipilimumab (Primary) ; T cell replacement therapy (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions
- 18 Dec 2018 Planned End Date changed from 1 Sep 2021 to 30 Sep 2021.
- 18 Dec 2018 Planned primary completion date changed from 1 Sep 2021 to 30 Sep 2021.
- 02 Nov 2018 Planned End Date changed from 1 Sep 2022 to 1 Sep 2021.